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Lea Galunić Bilić1 and Fedor Šantek1,2
1Department of Oncology and Radiotherapy, Zagreb University Hospital Centre, Zagreb, Croatia; 
2University of Zagreb, School of Medicine, Zagreb, Croatia
SUMMARY – Lymphomas are very radiosensitive and radiotherapy (RT) was the fi rst treatment 
modality that enabled cure. It is the most eff ective single modality for local control of lymphomas. 
However, as a local form of treatment, curative intention is only possible if all lymphoma tissue can be 
incorporated in the volume to be irradiated with the prescribed total irradiation dose. Th at is why RT 
is a single modality only in early stage of nodular lymphocyte predominance Hodgkin’s lymphoma 
and low grade non-Hodgkin’s lymphoma. In most patients, RT can be used as consolidation therapy 
after chemotherapy or as salvage after failure of chemotherapy. In the past two decades, irradiation 
techniques have been improved in order to spare critical tissues and reduce toxicity. Although eff ective, 
RT is a neglected modality of treatment because of the appearance of new drugs and fear of side ef-
fects after irradiation. Radiation has been shown to be eff ective in the treatment of all stages and forms 
of lymphoma. Study data are still mostly derived from patients that received supradiaphragmal RT; 
therefore, there is no agreement about the best management approach in patients with infradiaphrag-
mal lymphoma.
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Introduction
Lymphomas are very radiosensitive and radiother-
apy (RT) was the fi rst treatment modality that enabled 
cure. It is the most eff ective single modality for local 
control of lymphomas and an important part of the 
treatment for many patients. However, as a local form 
of treatment, curative intention is only possible if all 
lymphoma tissue can be incorporated into the volume 
that is irradiated with the total irradiation dose pre-
scribed. Today, RT as a single modality is used as the 
primary treatment in early stage of nodular lympho-
cyte predominance of Hodgkin’s lymphoma and in 
early stage of indolent non-Hodgkin’s lymphoma 
(NHL). In most patients, RT is part of combined 
treatment modalities as consolidation after chemo-
therapy. In patients with advanced stages of the dis-
ease, RT can be used as part of the planned treatment 
when RT is applied to high-risk recurrence sites and 
in cases of insuffi  cient response to chemotherapy1-5.
Radiation has been shown to be eff ective in the 
treatment of all stages and forms of lymphoma, but 
there is no consensus on the size of the fi eld or the dose 
administered in the abdominal area. All current knowl-
edge, radiation guidelines, and radiation side eff ects are 
retrieved for supradiaphragmal fi elds. Treatment of 
lymphoma in the abdominal area is the issue of existing 
controversy. Although eff ective, RT is a neglected form 
of treatment due to the appearance of new drugs and 
because of the fear of side eff ects after irradiation. In 
addition, there is no consensus about the use of RT as 
consolidation therapy after remission on chemotherapy 
or salvage RT when chemotherapy is unsuccessful.
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Radiotherapy in the Treatment of Lymphomas
Since the discovery of x-rays, RT has played an im-
portant role in the treatment of lymphomas. At the 
beginning, RT was limited to temporary control and 
palliation. In the 1960s,  RT was an almost exclusive 
modality in off ering a curative approach to early stage 
aggressive lymphomas6,7. In stage I of the disease, 
treatment modality that included Involved Field 
(IFRT) or Extended Field (EFRT) radiotherapy pro-
vided approximately 50% cure rate. In stage II NHL, 
RT alone could not achieve cure. In stage II patients, 
survival was only 20%. Due to the systemic nature of 
many types of NHL and the introduction of highly 
eff ective chemotherapy protocols, RT was neglected as 
a treatment option in NHL patients. In the 1990s, RT 
had a great return in the treatment of both aggressive 
and indolent NHL8,9.
Most relapses in patients treated only with RT 
were either extra nodal or out-of-fi eld. Th e advent of 
eff ective chemotherapy protocols for aggressive NHL 
has led to practical abandoning RT from the treatment 
of patients in early NHL stages. Several randomized 
studies showed that adjuvant chemotherapy followed 
by radiation resulted in signifi cantly better survival 
without relapse than just RT in early stages. In some 
studies, better survival without relapse resulted in bet-
ter overall survival10-14.
Adjuvant RT has become the standard of treat-
ment in early stages of aggressive NHL. Th is analysis 
is based on the two large randomized studies conduct-
ed by the Eastern Cooperative Oncology Group 
(ECOG) and Southwest Oncology Group (SWOG). 
Th ey demonstrated the superiority of the combined 
modality treatment versus chemotherapy alone in stage 
I and II high-grade lymphoma. Both studies con-
fi rmed the importance of adjuvant RT for primary in-
volvement of the disease in patients that achieved 
complete remission after a short (3-cycle) or long 
(8-cycle) chemotherapy protocol. Relatively low radia-
tion doses of 30 Gy were suffi  cient for patients with 
complete remission in the ECOG study. Higher radia-
tion doses (40-55 Gy) were applied in the SWOG 
study15,16.
Poor results achieved by radiation alone and the 
occurrence of relapse outside the radiation fi eld in ear-
ly stage NHL have demonstrated the systemic nature 
of aggressive lymphoma and stressed the importance 
of using chemotherapy in these situations. On the 
other hand, ECOG and SWOG studies emphasize 
that local therapy is an important component in the 
treatment, even in achieving complete remission in 
diseases that are primarily systemic15,16.
Th e role of RT in advanced stage aggressive NHL 
is still controversial. Some centers rarely recommend 
the use of adjuvant radiotherapy in patients with stage 
III and IV NHL, even in cases of bulky disease or par-
tial response to chemotherapy.
Th e standard treatment of patients in advanced 
stages of (III and IV) of aggressive NHL is a combi-
nation of chemotherapy. Th e most eff ective and com-
monly used is the R-CHOP (rituximab and cyclo-
phosphamide, doxorubicin, vincristine, prednisolone) 
regimen17. Th e use of RT as consolidation therapy in 
bulky disease or in patients with incomplete response 
was confi rmed in retrospective studies18. Some ran-
domized studies indicated that RT, if applied to the 
areas primarily aff ected by bulky disease, could signifi -
cantly contribute to relapse-free survival and overall 
survival in patients with complete remission upon che-
motherapeutic treatment19-23.
A study conducted in Mexico included 218 pa-
tients with stage IV diff use large B-cell lymphoma 
(DLBCL). Of these, 155 (71%) patients achieved 
complete remission on chemotherapy. Of the 155 pa-
tients that achieved complete remission, 88 (56%) pa-
tients presented bulky disease (>10 cm). Th ey were 
classifi ed into the group being observed or in the in-
volved-fi eld RT (IFRT) group receiving 40-50 Gy. 
After 5 years, 43 (72%) patients that received RT com-
pared to 45 (35%) patients in the non-irradiated group 
were alive and without signs of illness. Most relapses 
occurred in the primary area of the disease. Total sur-
vival was also better in the group of irradiated patients 
(81% vs. 55%; p<0.01)11. In a more recent study, 341 
patients with aggressive DLBCL and nodal bulky 
(>10 cm) disease with pathologically proven complete 
remission after chemotherapy were randomized to the 
irradiated group (IFRT, 40 Gy) or to the group being 
monitored. Th e 5-year event-free survival and overall 
survival were signifi cantly better in the group of ex-
posed patients (event-free survival 82% vs. 55%; 
p<0.001; overall survival 87% vs. 66%; p<0.01). RT 
was well tolerated and acute toxicity moderate19.
In a Milan study, 97 patients with stage III to IV 
DLBCL that were in complete remission after che-
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motherapy were either observed or received consolida-
tion RT. At 5 years, patients with bulky disease (<10 
cm) that received RT had a signifi cantly longer time to 
relapse and better overall survival (p<0.05) compared 
with patients that were not irradiated. A multivariate 
analysis showed that the use of RT was an indepen-
dent favorable prognostic factor for relapse (p<0.001) 
and survival (p<0.05)12.
Non-Hodgkin’s lymphoma is a systemic disease 
and all stages should be treated primarily with chemo-
therapy. RT to bulky or residual disease may improve 
the outcome of treatment. Th e potential benefi t of RT 
in advanced-stage disease is not approved in prospec-
tive randomized studies but the above data provide an 
adequate basis to justify the combined-modality ap-
proach in selected cases.
Radiation in the Abdominal Region
Since the introduction of RT in the treatment, in 
the 1950s and during the 1960s, the treatment of ab-
dominal presentation of the lymphoma was performed 
by irradiation of the entire abdomen. Patient tolerance 
to such treatment was poor. Patients had a signifi cant-
ly decreased blood cell count, diarrhea, nausea, feeling 
of increased tiredness, and loss of appetite24.
According to Surbone et al., 30% of patients had an 
abdominal mass at diagnosis and 40% were left with a 
radiographically detectable residual mass at clinical 
complete remission. Th e likelihood of a residual mass 
was much higher in patients with bulky disease23. 
 Results of several studies suggest that adding RT 
after chemotherapy treatment reduces the risk of 
local  recurrence and improves survival without re-
lapse11-13,18-20,24. Radiation is most eff ective in patients 
with poor prognostic factors (large tumor mass, exten-
sive nodal involvement, and advanced stage of disease) 
and need adjuvant treatment to consolidate disease 
remission. It is possible to apply a more intensive che-
motherapy scheme and bone marrow transplantation 
to achieve long lasting complete remission27. Although 
controversial, radiation in the abdominal area may be 
less toxic. Radiation can also be applied in refractory 
cases28,29. Many studies confi rm the viability and ef-
fectiveness of salvage radiation of tumor mass in the 
abdominal area30-34.
Th e fi rst article describing abdominal irradiation of 
NHL patients appeared in 1976. Inverted Y fi eld re-
sulted in 29% of relapses. It was considered that the 
cause of such a high rate of local recurrence was the 
lack of coverage of mesenteric lymph nodes in the in-
verted Y fi eld of irradiation31. Later, Brihi et al. demon-
strated that abdominal radiation was viable and eff ec-
tive in patients at a high risk of intra-abdominal re-
lapse, for the treatment of residual disease after che-
motherapy, and as palliative care that contributed to 
survival29.
Volume Defi nition and Side Eff ects 
of Infradiaphragmal Irradiation 
in Lymphoma Patients
Radiation techniques for lymphomas have signifi -
cantly changed over the last few decades. Partially, this 
is due to the reduction of the fi eld boundaries and be-
cause of the introduction of combined treatment mo-
dalities and new drugs, which have superseded irradia-
tion therapy as monotherapy.
Nowadays, large radiation fi elds that used to be ap-
plied are considered inadequate. Many of the historic 
concepts of dose and volume have been changed over 
the past few decades22,32,33. Irradiation therapy based 
on involved fi elds defi ned by anatomic landmarks and 
encompassing adjacent uninvolved lymph nodes is no 
longer appropriate for modern RT delivery.
Previously applied extended-fi eld (EFRT) and in-
volved-fi eld (IFRT) RT techniques have been replaced 
with smaller volumes based solely on detectable nodal 
enrolment at presentation (involved site-ISRT/in-
volved node-INRT)20,34-38. Th is is due to the general 
progress in radiation imaging and computer technol-
ogy, including the introduction of three-dimensional 
conformal RT (3D-CRT), intensity-modulated RT 
(IMRT), image-guided RT (IGRT) and 4-dimen-
sional RT (4D-RT). Advanced RT techniques allow 
the achievement of steep dose gradients in the radia-
tion fi eld along with spearing normal tissue. Initial 
 diagnostic imaging (computed tomography (CT), 
magnetic resonance imaging (MRI) and positron 
emission tomography (PET)) facilitates the target 
 volume defi nition, and signifi cant radiation dose re-
ductions at the organs at risk (kidneys, spinal cord, 
esophagus, liver and intestine). Reduction of the radia-
tion fi elds has reduced toxicity while maintaining a 
high cure rate in combined modality treatment. Th e 
aim is to reduce normal tissue exposure, but not to 
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compromise eff ective local control with such a reduced 
fi eld size.
Volumes are delineated according to the Interna-
tional Commission on Radiation Units Measurement 
(ICRU) and ICRU supplements39-41, based on defi n-
ing gross tumor volume (GTV) and clinical target vol-
ume (CTV). CTV has to be expanded to create plan-
ning target volume (PTV), which is used to defi ne 
dose coverage. Implementation of other imaging 
methods such as PET/CT has enabled more precise 
target borders and volume determination. Th anks to 
CT planning and the possibilities to design the radia-
tion plan in three dimensions, it is possible to defi ne 
the volumes and doses to each volume of irradiation 
much more precisely. Th ey allow the defi nition of 
planning volumes around the lymph node that have 
been aff ected, thus reducing the risk of toxicity and 
late side eff ects.
Pre-chemotherapy or preoperative GTV makes all 
areas aff ected by the disease before any intervention 
and should be labeled on the simulation CT because 
these volumes should be included in the CTV. CTV 
covers the original GTV (before any intervention), 
even if it extends beyond the original tissue and or-
gans. Normal structures such as kidneys and muscles, 
which obviously were not aff ected, although displaced 
by GTV, should be excluded from CTV, depending on 
clinical judgment. PTV should be created by adding 
margin taking into account uncertainties in position-
ing the patients and adjusting the photons during ir-
radiation delivery. Th is is the volume that has to be ir-
radiated to make the CTV irradiated with the pre-
scribed dose. PTV diff ers from institution to institu-
tion and needs to be calculated and determined in each 
case individually32,33.
Organs at Risk
Th e organs at risk (OAR) are critical organs or 
healthy organs near the irradiation fi eld and they can 
cause signifi cant morbidity if irradiated. Th is aff ects 
the treatment planning or determination of the radia-
tion dose. Current knowledge of radiation toxicity is 
derived from conventional and newer 3D-CRT data. 
Th e Quantitative Analyses of Normal Tissue Eff ects 
in the Clinic (QUANTEC) project has produced data 
that are currently used to predict RT side eff ects and 
the plausibility of evaluated treatment plans42. Before 
being approved, all RT treatment plans have to be 
evaluated for the probability of organ-specifi c radia-
tion toxicity. Th e clinician should consider dose-vol-
ume histograms and determine the likelihood of com-
plications of healthy tissue, and then approve the ra-
diation plan.
Th e number of organs at risk and the volume of 
normal tissue found in the radiation fi eld may be sig-
nifi cant. Due attention should be paid to short-term 
side eff ects and long-term morbidity, and accordingly 
target volume should be planned. Infradiaphragmal 
organs that limit the dose of radiation are spinal cord, 
kidneys, liver, and gastrointestinal system. Fortunately, 
doses that are used in lymphoma treatment are usually 
below the toxicity threshold for most organs. However, 
due to long survival rate and follow up of the patients, 
even small doses cannot be ignored.
Th ere are dose limits for the organs at risk that 
have to be estimated but these doses are easy to meet 
within the lymphoma RT plans as radiation doses are 
signifi cantly lower than in other solid tumors. How-
ever, dose limits and their compliance do not guaran-
tee optimization of the plan in terms of side eff ects 
and complications of treatment. Long survival rate 
after combined modality treatment poses the risk of 
secondary malignancies or morbidities occurring in 
the radiation fi eld.
Liver
Th e mean dose to the liver should be ≤30 Gy be-
cause in 5% of patients it may cause radiation-induced 
liver disease (anicteric hepatomegaly, ascites, increased 
alkaline phospahtase). It typically occurs between 2 
weeks and 3 months after RT43.
Kidneys
Kidneys are parallel organs, which means that one 
kidney can take over the role of the other one. So, ra-
diation-induced renal dysfunction can be expressed in 
various ways, including decrease in creatinine clear-
ance, biochemical changes and radiologic fi ndings to 
renal failure. QUANTEC has estimated a <5% risk of 
injury in 5 years when the mean kidney dose is limited 
to <18 Gy44.
Stomach and small bowel
Nausea and vomiting are radiation-induced acute 
toxicity. Th ey can occur within hours after RT to stom-
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ach or small-bowel. RT-induced injury to the stomach 
can range from self-limited mucosal infl ammation 
causing dyspepsia to ulceration and bleeding. RT-in-
duced small bowel mucositis can be expressed as 
cramping and diarrhea.
Late radiation-induced toxicity to the stomach in-
cludes dyspepsia and ulceration. A whole organ dose 
of 50 Gy has been associated with 2% to 6% risk of 
severe late toxicity.
Th e volume of the small bowel receiving relatively 
low doses of radiation plays a signifi cant role in the 
rate of acute toxicity. When contouring individual 
bowel loops, the rate of grade ≥3 acute toxicity is <10% 
when V15 <120 cc. When the entire potential space 
within the peritoneal cavity is contoured, a V45<195 
cc results in <10% acute toxicity45.
Pancreas
Radiation to para-aortic lymph nodes increases the 
risk of developing diabetes mellitus in 5-year Hodg-
kin’s lymphoma survivors. Radiation dose ≥36 Gy is 
associated with 2-fold increased risk of diabetes mel-
litus46.
Spinal cord
With conventional fractionation of 2 Gy per day 
including the full cord cross-section, a total RT dose of 
50, 60 and 70 Gy is associated with 0.2%, 6% and 50% 
rate of myelopathy, respectively. Re-irradiation data in 
animals and humans suggest partial repair of RT-in-
duced subclinical damage becoming evident about 6 
months post-RT and increasing over the next 2 years47.
Total dose to spinal cord in Hodgkin’s lymphoma 
and NHL patients is usually around 30 Gy, so my-
elopathy is not an issue.
Conclusion
Radiotherapy is an eff ective and safe treatment op-
tion for patients with localized abdominal lymphoma. 
Modern RT for lymphomas is a highly individualized 
treatment. Th e newly defi ned concept of involved site 
RT that uses modern imaging and RT techniques 
should be incorporated in everyday practice to mini-
mize the risk of long-term complications while achiev-
ing high local control and long-term survival. Th e op-
timal outcome for patients with lymphoma is only 
possible with collaborative multidisciplinary approach.
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Sažetak
RADIOTERAPIJA INFRADIJAFRAGMALNIH POLJA U BOLESNIKA S LIMFOMIMA: 
VOLUMENI I NUSPOJAVE
L. Galunić Bilić i F. Šantek
Limfomi su vrlo radiosenzitivni pa je radioterapija (RT) bila prva metoda liječenja koja je omogućavala izliječenje. Ona 
je i dalje najučinkovitiji pojedinačni modalitet liječenja limfoma. Međutim, RT je lokalna terapija i kao jedini oblik liječenja 
dolazi u obzir ako je moguće sve tumorsko tkivo uključiti u volumen koji će se zračiti. Stoga se danas RT primjenjuje kao 
primarni modalitet liječenja samo u ranom stadiju nodularne limfocitne predominacije Hodgkinova limfoma i indolentnih 
ne-Hodgkinovih limfoma. U većine bolesnika RT je dio kombiniranog modaliteta liječenja kao konsolidacija nakon kemo-
terapijskog liječenja. Kod bolesnika u uznapredovalim stadijima bolesti RT se može primijeniti kao dio planiranog liječenja 
kada se RT aplicira na mjesta visokog rizika za recidiv te u slučajevima insufi cijentnog odgovora na kemoterapiju. U protekla 
dva desetljeća tehnike zračenja su se promijenile te omogućavaju značajnije očuvanje rizičnih organa i smanjenje nuspojava. 
Iako učinkovita, RT je zanemaren modalitet liječenja zbog dostupnosti novih lijekova te zbog straha od nuspojava nakon 
zračenja. Zračenje je učinkovito u svim stadijima i oblicima limfoma. Dostupni podaci o učinkovitosti i nuspojavama RT 
odnose se na supradijafragmalna polja, zbog toga su potrebna istraživanja o najboljem RT pristupu liječenju bolesnika s 
 infradijafragmalnom prezentacijom limfoma.
Ključne riječi: Limfom, ne-Hodgkinov; Radijacijska tolerancija; Radioterapija
